Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVF containing autologous non-expanded ADSC is an autologous cell therapy investigational product developed by the Bangladesh Laser & Cell Surgery Institute & Hospital. It consists of the stromal vascular fraction (SVF) freshly isolated from a patient's own subcutaneous adipose tissue through a process of enzymatic digestion and centrifugation, without subsequent cell culture expansion. This heterogeneous mixture contains adipose-derived stem cells (ADSCs), endothelial progenitor cells, hematopoietic stem cells, and various immune cells. The therapy is administered intravenously and is being investigated for the treatment of Chronic Kidney Disease (CKD) stages 3-5. It is hypothesized that the ADSCs within the SVF exert regenerative, anti-fibrotic, and paracrine effects to improve renal function and slow disease progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose-derived stromal vascular fraction (Bangladesh Laser & Cell Surgery Institute & Hospital).